What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
Complaint alleges Unicycive Therapeutics, Inc. misled investors between December 29, 2025 and June 29, 2026; investors may seek lead plaintiff role by November 2, 2026 LOS ANGELES, Oct. 23, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today that the class...
Covered in this story
Call it yourself
No calls on $UNCY yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Unicycive Therapeutics →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.